Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.8.0 to v3.8.1; the clinical trial information remains unchanged.
    Difference
    0.0%
    Check dated 2026-11-18T00:58:14.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The clinical trial record for the duvelisib study is available, with its study design, eligibility criteria, outcome measures, locations, record history, and study documents.
    Difference
    60%
    Check dated 2026-11-10T19:32:31.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0. The study record page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T19:47:49.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    A sitewide NIH notice about terminology changes appears above the 403 error page, and the site revision label updates from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:19:35.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The footer now shows site revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-06T19:44:44.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page instead of the study record content. The new page presents a minimal error screen with a Home link.
    Difference
    15%
    Check dated 2026-09-22T22:53:55.000Z thumbnail image

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.